Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irbesartan - Sanofi aventis

Next Previous
X
Search
Drug Profile

Irbesartan - Sanofi aventis

Alternative Names: Aprovel; Avapro; BMS 186295; Irbetan; Karvea; SR 47436; Xarb

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Bristol-Myers Squibb; Sanofi; sanofi-aventis; Shionogi
  • Class Antihypertensives; Biphenyl compounds; Heart failure therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Hypertension
  • Discontinued Atherosclerosis

Most Recent Events

  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 23 Jan 2018 No development reported - Phase-II for Atrial fibrillation (Prevention) in Japan (PO)
  • 31 Mar 2016 Shionogi completes a phase II trial in Atrial fibrillation in Japan (UMIN000005205)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top